Export 10 results:
Author Title [ Type(Desc)] Year
Filters: Author is Anzala, Omu  [Clear All Filters]
Journal Article
G. Omosa-Manyonyi, Park, H., Mutua, G., Farah, B., Bergin, P. J., Laufer, D., Lehrman, J., Chinyenze, K., Barin, B., Fast, P., Gilmour, J., and Anzala, O., Acceptability and feasibility of repeated mucosal specimen collection in clinical trial participants in Kenya., PLoS One, vol. 9, no. 10, p. e110228, 2014.
W. Stevens, Kamali, A., Karita, E., Anzala, O., Sanders, E. J., Jaoko, W., Kaleebu, P., Mulenga, J., Dally, L., Fast, P., Gilmour, J., Farah, B., Birungi, J., Hughes, P., Manigart, O., Stevens, G., Yates, S., Thomson, H., von Lieven, A., Krebs, M., Price, M. A., Stoll-Johnson, L., and Ketter, N., Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials., PLoS One, vol. 3, no. 4, p. e2043, 2008.
G. Mutua, Farah, B., Langat, R., Indangasi, J., Ogola, S., Onsembe, B., Kopycinski, J. T., Hayes, P., Borthwick, N. J., Ashraf, A., Dally, L., Barin, B., Tillander, A., Gilmour, J., De Bont, J., Crook, A., Hannaman, D., Cox, J. H., Anzala, O., Fast, P. E., Reilly, M., Chinyenze, K., Jaoko, W., Hanke, T., and Group, T. Hiv- Core 0, Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults., Mol Ther Methods Clin Dev, vol. 3, p. 16061, 2016.
E. Karita, Ketter, N., Price, M. A., Kayitenkore, K., Kaleebu, P., Nanvubya, A., Anzala, O., Jaoko, W., Mutua, G., Ruzagira, E., Mulenga, J., Sanders, E. J., Mwangome, M., Allen, S., Bwanika, A., Bahemuka, U., Awuondo, K., Omosa, G., Farah, B., Amornkul, P., Birungi, J., Yates, S., Stoll-Johnson, L., Gilmour, J., Stevens, G., Shutes, E., Manigart, O., Hughes, P., Dally, L., Scott, J., Stevens, W., Fast, P., and Kamali, A., CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa., PLoS One, vol. 4, no. 2, p. e4401, 2009.
J. Nyombayire, Anzala, O., Gazzard, B., Karita, E., Bergin, P., Hayes, P., Kopycinski, J., Omosa-Manyonyi, G., Jackson, A., Bizimana, J., Farah, B., Sayeed, E., Parks, C. L., Inoue, M., Hironaka, T., Hara, H., Shu, T., Matano, T., Dally, L., Barin, B., Park, H., Gilmour, J., Lombardo, A., Excler, J. - L., Fast, P., Laufer, D. S., and Cox, J. H., First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens., J Infect Dis, vol. 215, no. 1, pp. 95-104, 2017.
G. Mutua, Sanders, E., Mugo, P., Anzala, O., Haberer, J. E., Bangsberg, D., Barin, B., Rooney, J. F., Mark, D., Chetty, P., Fast, P., and Priddy, F. H., Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers., PLoS One, vol. 7, no. 4, p. e33103, 2012.
W. Jaoko, Nakwagala, F. N., Anzala, O., Manyonyi, G. Omosa, Birungi, J., Nanvubya, A., Bashir, F., Bhatt, K., Ogutu, H., Wakasiaka, S., Matu, L., Waruingi, W., Odada, J., Oyaro, M., Indangasi, J., Ndinya-Achola, J., Konde, C., Mugisha, E., Fast, P., Schmidt, C., Gilmour, J., Tarragona, T., Smith, C., Barin, B., Dally, L., Johnson, B., Muluubya, A., Nielsen, L., Hayes, P., Boaz, M., Hughes, P., Hanke, T., McMichael, A., Bwayo, J., and Kaleebu, P., Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa., Vaccine, vol. 26, no. 22, pp. 2788-95, 2008.
W. Jaoko, Karita, E., Kayitenkore, K., Omosa-Manyonyi, G., Allen, S., Than, S., Adams, E. M., Graham, B. S., Koup, R. A., Bailer, R. T., Smith, C., Dally, L., Farah, B., Anzala, O., Muvunyi, C. M., Bizimana, J., Tarragona-Fiol, T., Bergin, P. J., Hayes, P., Ho, M., Loughran, K., Komaroff, W., Stevens, G., Thomson, H., Boaz, M. J., Cox, J. H., Schmidt, C., Gilmour, J., Nabel, G. J., Fast, P., and Bwayo, J., Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa., PLoS One, vol. 5, no. 9, p. e12873, 2010.
P. Mwangi Mugo, Sanders, E. J., Mutua, G., van der Elst, E., Anzala, O., Barin, B., Bangsberg, D. R., Priddy, F. H., and Haberer, J. E., Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya., AIDS Behav, vol. 19, no. 5, pp. 794-801, 2015.
A. Spentzou, Bergin, P., Gill, D., Cheeseman, H., Ashraf, A., Kaltsidis, H., Cashin-Cox, M., Anjarwalla, I., Steel, A., Higgs, C., Pozniak, A., Piechocka-Trocha, A., Wong, J., Anzala, O., Karita, E., Dally, L., Gotch, F., Walker, B., Gilmour, J., and Hayes, P., Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates., J Infect Dis, vol. 201, no. 5, pp. 720-9, 2010.